Nuvation Bio (NUVB)
(Delayed Data from NYSE)
$2.41 USD
+0.07 (2.99%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $2.41 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NUVB 2.41 +0.07(2.99%)
Will NUVB be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for NUVB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NUVB
Nuvation Bio Inc. (NUVB) Is Up 25.28% in One Week: What You Should Know
NUVB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for NUVB
Navigating Legal Uncertainty: Nuvation Bio Inc.’s Chinese Operations and the Shifting Landscape of China’s Civil Law System
Jefferies Releases a Buy Rating on Nuvation Bio (NUVB)
Nuvation Bio price target lowered by $1 at H.C. Wainwright, here's why
Nuvation announces pooled data from pivotal Phase 2 TRUST-I, TRUST-II studies
Positive Pooled Data from Nuvation Bio?s TRUST-I and TRUST-II Studies Highlight Taletrectinib?s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024